S1803: Phase III Study of Daratumumab/rHuPH20 (NSC – 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Meyloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Objective

Clinical Trial Details »

Temporarily closed to accrual starting 29 March 2023.  

Principal Investigator(s)

Xavier Andrade-Gonzalez, MD

Clinical Trial Categories

• Multiple Myeloma

Contact

Hematology Research Coordinators at 605-322-3090
or hematologyresearch@avera.org